Stem Cell and Regenerative Therapy Market Report to Describe Major Companies and Their Strategies (2019-2024) – PRnews Leader

Theglobal stem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Continue reading here:
Stem Cell and Regenerative Therapy Market Report to Describe Major Companies and Their Strategies (2019-2024) - PRnews Leader

Baby Gets Early Stem Cell Transplant to Treat Rare Disease Thanks to Newborn Screening – University of Michigan Health System News

At birth, Minette looked perfectly healthy, and her parents took their 7 pound, 9- ounce, brown-eyed baby girl home thinking all was well.

But her newborn screening test revealed something different.

The results indicated Minette had a rare lysosomal storage disease known as mucopolysaccharidosis type I, or MPS-1. Babies usually dont show any symptoms at birth, but the condition is progressively debilitating, eventually causing permanent damage to mental development, organ function and physical abilities.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunes, Google Play and Stitcher.

And at nine days old in January, 2019, after a series of tests run by the newborn screen follow up team in pediatric genetics at Michigan Medicine C.S. Mott Childrens Hospital, Minette was officially diagnosed with MPS-1.

There were no signs of this disease during pregnancy or after her birth, says her mother Samantha Mejia, of West Bloomfield, Mich.

It was so important that we identified it early so she could get treatment that would give her a better chance of living a more normal life.

MPS-1 means the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules (glycosaminoglycans) within structures called lysosomes. Lysosomes are essentially the bodys recycling centers large molecules go in and come out small enough so the body can use them.

Like Podcasts? Add the Michigan Medicine News Break oniTunes or anywhere you listen to podcasts.

When these molecules cant be broken down, they build up in the cell, causing many organs and tissues of the body to become enlarged, damaged and unable to work properly. Some children may develop mild to moderate mental impairment or learning difficulties, respiratory problems, sleep apnea and heart disease.

In severe cases like Minettes, children stop developing between ages 2-4, which is followed by progressive mental decline including loss of physical abilities and language skills.

MPS-1 was added to the Michigan newborn screen in August, 2017 just a little more than a year before Minette was born joining a list of more than 50 disorders that can now be detected through a simple blood test after birth.

Prior to being added to the newborn screen, many children were often diagnosed between ages one-and-a-half and three years old because they start losing developmental milestones or begin showing certain facial features as a result of glycosaminoglycans storage, such as thickened nostrils, lips or ears.

The clinical diagnosis of MPS-1 is often delayed because the symptoms tend to be non-specific early on. Newborn screening is crucial for making an early diagnosis and initiating treatment, which significantly alters the long term outcomes for patients, says Rachel Fisher, pediatric genetic counselor at Mott and a lysosomal storage disorder newborn screen coordinator for the state of Michigan.

Because of Minettes early diagnosis, her Mott care teams could quickly take next steps for treatment. She started enzyme therapy within six weeks, and at three months of age underwent four days of chemotherapy before ultimately getting a hematopoietic stem cell transplant to help replace the enzyme her body was missing.

See the article here:
Baby Gets Early Stem Cell Transplant to Treat Rare Disease Thanks to Newborn Screening - University of Michigan Health System News

Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn – GlobeNewswire

October 22, 2020 09:00 ET | Source: BrainStorm Cell Therapeutics Inc.; Catalent

SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced an agreement for the manufacture of NurOwn, BrainStorms autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease.

NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection. The therapy has received Fast Track status from the U.S. FDA for ALS and has also been granted Orphan Drug Status for ALS by both the FDA and the European Medicines Agency. BrainStorm is currently completing a 200-patient, double-blind, placebo-controlled, repeat-dosing NurOwn Phase 3 study in the U.S.

As part of its commitment, Catalent will undertake the transfer of the manufacturing process to, and provide future CGMP clinical supply of NurOwn from, its new, 32,000 square-foot cell therapy manufacturing facility in Houston, Texas. On completion of the clinical trials and in anticipation of potential approval of NurOwn, the companies will look to extend the partnership to include commercial supply from the Houston facility.

We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.

Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, Our experience in cell therapy development, and the manufacturing capabilities that our newly constructed, state-of-the-art facility in Houston offers, position us to best support BrainStorm, with its leading therapeutic candidate for ALS treatment. We look forward to partnering with BrainStorm and providing our stem cell manufacturing expertise as we work to optimize production and streamline the products path towards commercial launch.

About Catalent Cell & Gene Therapy

With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Media Contacts:

See the original post here:
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire

Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors – GlobeNewswire

October 22, 2020 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

BOSTONandLONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced that the companys chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicines (ARM) 2021 board of directors. In collaboration with the executive committee and board of directors, Dr. Gaspar will provide guidance supporting formation and implementation of ARMs strategic priorities and focus areas over the coming year.

I am honored to join the Alliance for Regenerative Medicines board at this pivotal time for cell and gene therapies, said Bobby Gaspar, CEO of Orchard. As more one-time, potentially curative medicines move toward commercialization, its imperative that we work together to meet the needs and challenges of a society accustomed to using chronic therapies to treat diseases. I look forward to collaborating with industry peers toward our common goal of bringing innovative treatment options to patients and families.

ARM is the leading international multi-stakeholder advocacy organization for the cell and gene therapy sector, promoting legislative, regulatory, and reimbursement initiatives to facilitate access to life-giving advances in regenerative medicine worldwide.

We are pleased to welcome Bobby Gaspar as one of the accomplished executives joining the 2021 ARM board of directors, said Janet Lambert, CEO of ARM. As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative cell and gene therapies to patients around the world.

About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter andLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, and the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

Visit link:
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine's 2021 Board of Directors - GlobeNewswire

Be Biopharma debuts with $52M to advance engineered B-cell therapies – FierceBiotech

You may have heard of T cells, but Aleks Radovic-Moreno, Ph.D., Be Biopharmas co-founder, president and director, is betting on B cells as the future of cell therapies.

Our mission is to develop what we see as a new class of cell medicines that have a broad new pharmacology, he said of B cells potential. We think it's a big new white space that's enabled by the rich biology of these cells.

The Cambridge, Massachusetts-based company is capitalizingearly on research by scientists at the University of Washington School of Medicine. With a $52 million series A round in the bank, it'smaking a beeline for the clinic.

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Why the enthusiasm around B cells? The wayRadovic-Moreno sees it, they'rethe cellular gadget, if you will, that's really good at making large amounts of protein, and they also traffic to where you want them to go."

When we think about it from a drug development standpoint, now you have a system that can make a protein that you want in high quantities in places where you want it to be made, he added.

B cells may also be useful for targeting specific tissues and modulating microenvironments, or [talking] to the cells that are nearby, he said.

One of the biggest challenges to bringing Be Bio to fruition was making the products themselves. Theyre harder to engineer than other cell types thanksto their intrinsic biology, Radovic-Moreno said. Theyre also hard to make correctly and in large quantities, challenges the company only recently overcame.

Those two are the final two bottlenecks that were preventing B cells from being a viable stem cell therapy modality, he said.

RELATED: Q32 debuts with $46M to 'rebalance' innate and adaptive immunity

The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene. B-cell therapy could eliminate the need for patients with monogenic disorders who are missing proteins to get biweekly four-hour infusions.

And that's not all. It couldalso eliminate the need for bone marrow transplants in these patients, as well asthe need for a pre-therapy round of chemotherapy, otherwise known as conditioning. For cancer patients who need conditioningahead of a stem cell treatment, the regimencan be deadly up to 10% of the time.

That's extraordinary if you think about a therapy killing patients 10% of the time, Radovic-Moreno said.

Beyond pushing Be'spipeline toward the clinic, the new fundingfrom Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and other investorswill bankroll potential partnerships and build out the company's team.

The most important thing is to build a great company, hire the best people. We want to be the best B-cell engineers in the world and in history, Radovic-Moreno said. We want to fully capitalize on the timing of this, given that it's a very kind of unusual place to be in this time and age of biotech, where you're sitting right in front of this massive blue wave, big blue ocean of possibilities so big.

Here is the original post:
Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech

Five Penn faculty elected to the National Academy of Medicine – Penn Today

Five faculty members from Penn have been elected to the National Academy of Medicine (NAM), one of the nations highest honors in the fields of health and medicine. William Beltran of the School of Veterinary Medicine, Matthew McHugh of the School of Nursing, and Ronald DeMatteo, Raina Merchant, and Hongjun Song of the Perelman School of Medicine are among the 100 new members, elected by current NAM members.

Election recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.

William Beltran is professor of ophthalmology in the Department of Clinical Sciences and Advanced Medicine and director of the Division of Experimental Retinal Therapies at Penn Vet. His research focuses on inherited retinal degeneration, a major cause of blindness in dogs and humans worldwide. Specifically, he has investigated the signaling pathways affected by X-linked retinitis pigmentosa and autosomal dominant retinitis pigmentosa, two of the most common forms of inherited retinal degeneration in humans. Working in canines, who suffer from forms of retinal degeneration that closely mimic the human diseases, he has helped develop effective gene therapies with promising results for treating both early- and late-stage disease.

Ronald Paul DeMatteo is the John Rhea Barton Professor and chair in the Perelman School of Medicines Department of Surgery. DeMatteo served as principal investigator on three national trials for the adjuvant drug imatinib for gastrointestinal stromal tumor, the most common human sarcoma. His work led to imatinibs approval for adjuvant use by the FDA and established the standard-of-care for GIST, combining surgery and imatinib. DeMatteo is also being recognized for his work to define the immune response to GIST and its modulation by targeted therapy.

Matthew McHugh is the Independence Chair for Nursing Education and professor of nursing at Penn Nursing, associate director of the Center for Health Outcomes and Policy Research (CHOPR), and senior fellow of the Leonard Davis Institute of Health Economics. As principal investigator on multiple large-scale studies funded by the National Institutes of Health, Agency for Healthcare Research and Quality, and Robert Wood Johnson Foundation, McHughs work has advanced the field of nursing outcomes and policy research by showing the value of investing in nursing to achieve a higher functioning health care system. In addition to findings from direct evaluations of nurse staffing ratio laws, research from McHugh and colleagues from the CHOPR at Penn Nursing has informed legislation proposed in multiple states and countries on safe nurse-staffing levels.

Raina Merchant is associate vice president and director of the Center for Digital Health in Penn Medicine and associate professor of emergency medicine in the Perelman School of Medicine.Merchants work has sought to gain insights through digital media about important health trends, and she is recognized for developing, deploying, evaluating, and refining novel tools and techniques to promote individual and population health. Some of her projects in this arena include tracking both physical and mental health symptoms via Twitter during the COVID-19 pandemic, determining keywords and phrases that could be used to flag depression via Facebook posts, and a crowdsourcing initiative called the MyHeartMap Challenge to construct an online map of automated external defibrillators across Philadelphia. In 2019, Merchant was named to NAMs class of Emerging Leaders of Health and Medicine Scholars.

Hongjun Song is the Perelman Professor of Neuroscience in the Perelman School of Medicines Department of Neuroscience and co-director of the Institute for Regenerative Medicine Neurodevelopment and Regeneration Program. His work focuses on neural stem cell regulation and neurogenesis and their effects on neural function as well as epigenetic and epitranscriptomic mechanisms and their role in the mammalian nervous system. He is being recognized for revealing unexpected dynamics and plasticity of the neuronal epigenome, as well as its functions under physiological and pathological conditions. In response to urgent global health concerns, his team made a series of timely discoveries on the pathogenesis, mechanisms, and treatment of Zika virus infections.

See the original post here:
Five Penn faculty elected to the National Academy of Medicine - Penn Today

Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors – BioSpace

Oct. 20, 2020 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Matthew R. Patterson, a biotechnology executive with nearly 30 years of experience in research, development, and commercialization of innovative treatments, to its Board of Directors.

Matt is a highly respected leader in biotech, and for good reason, said Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer. His expertise, guidance, and insights will be critical as we continue to advance our science towards the goal of developing potentially transformative therapies for patients with blood cancers.

Mr. Patterson has held senior leadership positions in both private and publicly-traded biotechnology companies. He is the co-founder of Audentes Therapeutics and was its Chief Executive Officer for eight years until its acquisition by Astellas Pharma in 2020; he also chaired the companys Board of Directors and continues to serve as a strategic advisor to the company. Additionally, he is a member of the Board of Directors of Homology Medicines, Inc., and the Board of Directors of 5:01 Acquisition Corp. Mr. Patterson also currently serves as the Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector.

Prior to Audentes, Mr. Patterson was an entrepreneur-in-residence with OrbiMed. Earlier in his career, he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Mr. Patterson received his bachelors degree in biochemistry from Bowdoin College.

Vors innovative approach to cell therapy and passionate team have the potential to transform the lives of cancer patients, Mr. Patterson said. I am excited to provide guidance and mentorship to Robert and the team as they continue to build a world class cell therapy company.

About Vor Biopharma

Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies, and CAR-T cell treatments.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.

About VOR33

Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, we believe that CD33 will become a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from acute myeloid leukemia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005188/en/

Read more from the original source:
Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors - BioSpace

Harvard Business School and Harvard’s Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to…

BOSTON, Oct. 20, 2020 /PRNewswire/ --Harvard Business School (HBS) and Harvard's Department of Stem Cell and Regenerative Biology (HSCRB) have received a $25 million gift from Chris and Carrie Shumway (MBA 1993) to fund programs promoting leadership in life sciences, including the MS/MBA Biotechnology: Life Sciences, a joint degree offered by HBS and the Graduate School of Arts and Sciences and Harvard Medical School through HSCRB. The gift will help bridge the worlds of business and science by fostering an environment of collaboration and innovation at HBS and across Harvard, supporting work on pathbreaking research and educating a new generation of leaders in the life sciences. The gift will provide support for curriculum development and programming, faculty research, and student financial aid.

"Every day we are contending with the challenges posed by a worldwide pandemic and seeing firsthand the importance of strong connections between the lab bench and the private sector," said Harvard President Larry Bacow. "The Shumways have given us the opportunity to think deeply about how we train leaders at this intersection that will only grow in complexity and importance. We are grateful for their foresight and their exceptional generosity."

"This gift will provide the University with the resources to support future leaders in life sciences, dramatically increase innovation and the commercialization of new discoveries, and efficiently and quickly take transformative discoveries from the laboratory to patients and the marketplace," said HBS Dean Nitin Nohria. "The world needs more business leaders working at the intersection of science and society, with deep understanding of not only biotechnology and life sciences, but the management skills needed to help these important companies thrive."

To meet this need, the MS/MBA Biotechnology: Life Sciences Program, welcomed its first cohort of students this past August. In supporting financial aid that will cover the incremental costs of the MS/MBA program for these students, this gift will enable Harvard to attract and support outstanding students who already have experience and knowledge in life sciences. To recognize this support, the students in this program will be known as Shumway Fellows and this program will prepare them to take on leadership roles in biotechnology and life sciences organizations.

The program builds upon students' existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to launch, grow, and lead transformative organizations that will advance new drug discoveries or therapeutics. Students in the program study general management at HBS and life-sciences at HSCRB, which is a joint department of Harvard's Faculty of Arts and Sciences (FAS) and Harvard Medical School (HMS). They benefit from the leadership of program co-chairs Amitabh Chandra (Henry and Allison McCance Professor of Business Administration at HBS and the Ethel Zimmerman Winer Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government) Mark Fishman (Professor of Stem Cell and Regenerative Biology at Harvard University and Chief of Pathways Consult Service at Massachusetts General Hospital), and Douglas Melton (Xander University Professor at Harvard University and Co-Director of the Harvard Stem Cell Institute).

"The MS/MBA program is a collaborative effort from several schools across Harvard to fill a unique need we see in the industry," said Emma Dench, dean of GSAS. The program provides students with the opportunity to become conversant in both biomedical science and business, and this generous gift will help to ensure that we can prepare them to lead in the rapidly growing life sciences fields."

"The future of life sciences innovation will increasingly require deep scientific knowledge coupled with targeted business acumen," said George Q. Daley, dean of HMS. "With this joint degree, Harvard will be uniquely positioned to educate students to lead at this nexus."

"Sometimes it is at the intersection of disciplines where we find opportunities to ask new questions that have the potential to completely change the way we think about a problem," said Edgerley Family Dean of the Faculty of Arts and Sciences Claudine Gay. "This gift will enable Harvard to attract and support talented scholars in the life sciences and equip them with the tools they need to work at the interface of business and life sciences, asking the new questions that promote discovery and innovation in this important area."

"Harvard has created an exceptional ecosystem that can develop and cultivate talented professionals across medicine, business and life sciences who are best positioned to tackle the world's biggest global health challenges today and in the future," said Chris Shumway, managing partner and founder of Shumway Capital. "As Harvard is geographically situated at the epicenter of the life sciences community with access to some of the world's leading hospitals, pharma and biotechnology companies, we believe a tremendous opportunity exists to foster cross-pollination of ideas by marshalling the resources of Harvard and connecting with industry leaders to quickly understand and solve problems."

The gift will also support HBS as it engages and works closely with entrepreneurs and practitioners in the field on the creation of new research and the development of executive education training to serve their unique needs.

"The acceleration of global health issues, including the current pandemic, demonstrates the need for entrepreneurial thinking," Chris Shumway added. "Leaders born out of these programs will be equipped to drive organizations at the forefront of groundbreaking discoveries with the mindset needed to solve complex problems worldwide."

As an entrepreneur and Managing Partner of Shumway Capital, Chris Shumway has invested in, advised, and built growth businesses for over 25 years, including in biotechnology and life sciences. The Shumways are long-time supporters and advocates for philanthropic initiatives. As strong proponents of education reform, they established the Shumway Foundation with the primary goal of helping to break the cycle of poverty through better opportunities in education. The Shumway Foundation also actively supports other results-based non-profit organizations.

ABOUT HARVARD BUSINESS SCHOOL:Founded in 1908 as part of Harvard University, Harvard Business School is located on a 40-acre campus in Boston. Its faculty of more than 200 offers full-time programs leading to the MBA and doctoral degrees, as well as more than 70 open enrollment Executive Education programs and 55 custom programs, and Harvard Business School Online, the School's digital learning platform. For more than a century, HBS faculty have drawn on their research, their experience in working with organizations worldwide, and their passion for teaching to educate leaders who make a difference in the world, shaping the practice of business and entrepreneurship around the globe.

ABOUT THE GRADUATE SCHOOL OF ARTS AND SCIENCES:Since it was first established in 1872, the Graduate School of Arts and Sciences (GSAS) has grown into a leading institution of graduate study. GSAS offering PhD and select master's degrees in 58 departments and programs that connect students with all parts of Harvard University. Each year, GSAS identifies and attracts the most promising students to form a dynamic and diverse global community, shaping them into visionary scholars, innovative educators, and creative leaders while encouraging them to cross disciplinary boundaries. Graduate students are at the heart of Harvard's excellence in research and education, studying with distinguished faculty and accessing world-renowned research centers, laboratories, scholarly collections, and museums.

ABOUT HARVARD MEDICAL SCHOOL:Harvard Medical School has more than 11,000 faculty working in the 11 basic and social science departments comprising the Blavatnik Institute and at the 15 Harvard-affiliated teaching hospitals and research institutes: Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Cambridge Health Alliance, Dana-Farber Cancer Institute, Harvard Pilgrim Health Care Institute, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear/Schepens Eye Research Institute, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Spaulding Rehabilitation Network and VA Boston Healthcare System. https://hms.harvard.edu/.

ABOUT HARVARD'S DEPARTMENT OF STEM CELL AND REGENERATIVE BIOLOGY (HSCRB):HSCRB has a mission to illuminate the workings of human health and disease, in both basic discovery and clinical settings. As a joint department between Harvard's Faculty of Arts and Sciences and Harvard Medical School, we are committed to transforming medicine by cultivating a deeper knowledge of stem cell and regenerative biology, and to training the next generation to explore new frontiers in biomedical science. HSCRB research bridges academic inquiry and biomedical R&D, with technology and entrepreneurship integrated into many elements of our teaching and research.

Media Contact:Mark Cautela [emailprotected] 617-495-5143

SOURCE Harvard Business School

Read the rest here:
Harvard Business School and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from Chris and Carrie Shumway to...

Human Embryonic Stem Cells (HESC) Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: ESI BIO, Thermo Fisher, BioTime,…

Impact of COVID-19 Global Human Embryonic Stem Cells (HESC) Market Size, Status and Forecast 2020-2026

This report studies theHuman Embryonic Stem Cells (HESC)market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Human Embryonic Stem Cells (HESC) market analysis segmented by companies, region, type and applications in the report.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

The major players covered in Human Embryonic Stem Cells (HESC) Markets: ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife, and more

The final report will add the analysis of the Impact of Covid-19 in this report Human Embryonic Stem Cells (HESC) industry.

Get a Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-human-embryonic-stem-cells-hesc-market-insights-forecast-to-2025?utm_source=eurowire&utm_medium=42

Human Embryonic Stem Cells (HESC)Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Human Embryonic Stem Cells (HESC) Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

This report focuses on the globalHuman Embryonic Stem Cells (HESC)status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Embryonic Stem Cells (HESC) development inUnited States, Europe, China, Japan, Southeast Asia, India, and Central & South America.

Market segment by Type, the product can be split into

Market segment by Application, split into

Research Objectives:

TheHuman Embryonic Stem Cells (HESC)market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Key questions answered in the report include:

Table of Contents

Chapter 1:GlobalHuman Embryonic Stem Cells (HESC)Market Overview

Chapter 2:Human Embryonic Stem Cells (HESC) Market Data Analysis

Chapter 3:Human Embryonic Stem Cells (HESC) Technical Data Analysis

Chapter 4:Human Embryonic Stem Cells (HESC) Government Policy and News

Chapter 5:Global Human Embryonic Stem Cells (HESC) Market Manufacturing Process and Cost Structure

Chapter 6:Human Embryonic Stem Cells (HESC) Productions Supply Sales Demand Market Status and Forecast

Chapter 7:Human Embryonic Stem Cells (HESC) Key Manufacturers

Chapter 8:Up and Down Stream Industry Analysis

Chapter 9:Marketing Strategy -Human Embryonic Stem Cells (HESC) Analysis

Chapter 10:Human Embryonic Stem Cells (HESC) Development Trend Analysis

Chapter 11:Global Human Embryonic Stem Cells (HESC) Market New Project Investment Feasibility Analysis

Inquire More about This Report @ https://www.reportsandmarkets.com/enquiry/global-human-embryonic-stem-cells-hesc-market-insights-forecast-to-2025?utm_source=eurowire&utm_medium=42

About Us:

Reports and Marketsis not just another company in this domain but is a part of a veteran group calledAlgoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

View post:
Human Embryonic Stem Cells (HESC) Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: ESI BIO, Thermo Fisher, BioTime,...

Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Potential Growth, Competitive Landscape and Development of Industry by 2025 Wall Street…

Oct 20, 2020 1:54 AM ET iCrowd Newswire Oct 20, 2020

The latest report titled Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 by Company, Type and Application, Forecast to 2025, prepared by MarketsandResearch.biz is widely known for its accuracy and factual figures that have been shown through a concise graphical representation, tables, and figures. This recently updated report highlights vital information, such as market drivers, challenges, drivers, risks, competitive situation, vendor landscape, and more. The report offers a brief review and an extensive analysis of the global Induced Pluripotent Stem Cells (iPSCs) market top developers, production value, key regions, and growth rate. The study displays a clear picture of the developments of the products and its market performance over the last few years. The latest developments and groundbreaking strategic changes mentioned in this report allow our clients to improve their decision-making skills.

Manufacturers Portfolio: This report covers complete portfolios of all local and global manufacturers along with SWOT analysis, production value and capacity, product catalog, and other important details of their business. The companies included in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the global Induced Pluripotent Stem Cells (iPSCs) market. The percentage splits, market shares, growth rate, and breakdowns of the product markets are determined.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/117651

This report covers leading companies associated in the worldwide Induced Pluripotent Stem Cells (iPSCs) market: Fujifilm Holding Corporation (CDI), ReproCELL, Astellas Pharma Inc, Ncardia, Cell Inspire Biotechnology, Sumitomo Dainippon Pharma, Pluricell Biotech, Fate Therapeutics, Inc

On the basis of end-use industry, the global market report offers insights into the opportunities and new avenues of following key segments: Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine, Others

In order to analyze growth prospects in the aforementioned segments in the global market, the study assesses demand and consumption patterns of the following product segments: Human iPSCs, Mouse iPSCs

To have a better understanding of regional dynamics, the global Induced Pluripotent Stem Cells (iPSCs) market covers the following geographies: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Moreover, the report examines such important elements such as market demands, trends, and product developments, various organizations, and global market effect processes. The report assesses various critical constraints, such as item price, production capacity, profit & loss statistics, and global Induced Pluripotent Stem Cells (iPSCs) market delivery channels. The research study encourages the consumer to develop a well-structured strategy to grow and improve their companies in the expected time from 2020 to 2025.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/117651/global-induced-pluripotent-stem-cells-ipscs-market-2020-by-company-type-and-application-forecast-to-2025

Key Takeaways:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketsandresearch.biz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [emailprotected].

Read the original here:
Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Potential Growth, Competitive Landscape and Development of Industry by 2025 Wall Street...